PDA Options: To view abstract content with the ability to bookmark to set up an itinerary that you can download and save to your PDA or computer, click on MY ITINERARY in the banner above; then proceed by searching the online database.



Sponsored by
Category Index Expand / Collapse All
Click on one of the following letters below to display a list of alphabetized categories.
Click the checkbox next to each item to bookmark.
A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
 A


Expand/Collapse Item Adjuvant Chemotherapy
Expand/Collapse Item Adjuvant Endocrine Therapy
Expand/Collapse Item Adjuvant Therapy - Other
Expand/Collapse Item Adjuvant Therapy - Targeted
Expand/Collapse Item Advanced Chemotherapy
Expand/Collapse Item Advanced Endocrine Therapy
Expand/Collapse Item Advanced Therapy - Targeted
Expand/Collapse Item Alternative Therapies
Expand/Collapse Item Angiogenesis
  [901] Angiotensin-(1-7) inhibits triple negative tumor growth through the inhibition of angiogenesis and a reduction in placental growth factor PlGF.
  [903] Bevacizumab (BV) maintenance therapy significantly delays disease progression (PD) or death compared with placebo (PL) in the AVADO trial (BV + docetaxel [D] vs D + PL in 1st-line HER2-negative locally recurrent [LR] or metastatic breast cancer [mBC]).
  [904] The role of VEGFR-2 genetic variation in breast cancer progression.
  [907] The correlation of tumor vascularity as imaged by near-infrared technology with tissue distribution of angiogenic and growth promoters.
  [1027] Efficacy of bevacizumab (BV) plus docetaxel (D) does not correlate with hypertension (HTN) or G-CSF use in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) in the AVADO phase III study.
  [1028] VEGF, VEGFR2 and HIF-1α expression in circulating tumor cells (CTCs) of breast cancer patients.
  [1029] Angiogenic escape and tumour progression in two patients with metastatic breast cancer receiving bevacizumab treatment.
  [1030] Safety of surgery in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) treated with docetaxel (D) plus bevacizumab (BV) or placebo (PL) in the AVADO phase III study.
  [1031] The effect of raloxifene on vascular endothelial growth factor expression in breast carcinomas of postmenopausal women.
  [1032] Mechanisms of nab-paclitaxel and bevacizumab cooperation in inhibition of breast tumor growth and metastasis.
  [1033] Anti-angiogenic effects of tamoxifen in breast cancer by decreased secretion and reduced nuclear accumulation of angiogenin.
  [1034] Selective inhibition of VEGFR2 activity with a human anti-VEGF monoclonal antibody decreases tumor growth and macrophage infiltration in an orthotopic model of breast cancer.
  [1035] Effect of anticoagulation therapy on bleeding and thromboembolic events (TEs) in the AVADO phase III study of docetaxel (D) ± bevacizumab (BV) in inoperable locally recurrent (LR) or metastatic breast cancer (mBC).
  [1036] The effect of tetrathiomolybdate on circulating endothelial progenitor cells in patients with breast cancer at high risk of recurrence.
  [1037] Angiogenesis in breast cancer: comparison between three vascular endothelial markers.
 
 

Abstract Sessions | Support | FAQ | Privacy Policy

San Antonio Breast Cancer Symposium
7703 Floyd Curl Dr. Mail Code 8224
San Antonio, TX 78229 USA
http://www.sabcs.org
Technical Support • © 2010 Marathon Multimedia, a Learner’s Digest International business. • All rights reserved